|
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The present results indicated PRCP rs7104980 can be considered as a marker for EH and Hap3 GAGCACTAACA (PRCP) and Hap16 TTTA (CMA1) might be associated with EH in Chinese Han population.
|
22679278 |
2013 |
|
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that the rs9607267 of the HMOX1 gene was significantly associated with essential hypertension (EH) and the Hap3(T-C-G) of the HMOX1 gene was also significantly associated with the risk of EH.
|
19886851 |
2009 |
|
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Compared with the most common Hap2 CAGC, Hap1 AGAC and Hap3 CGAC, which carry the susceptible rs2304595 G allele and rs4253325 A allele, were found to significantly increase the risk of essential hypertension with adjusted odds ratios equal to 1.37 and 1.17, respectively (P < 0.0001 and 0.028).
|
17318641 |
2007 |
|
Agranulocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The presence of HAP 3 (HAP3) in the FMO3 gene HAP was statistically associated with ATD-induced agranulocytosis (p = 0.038, permutation p value).
|
30814476 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Nuclear factor-Y (NF-Y) consists of three evolutionary conserved subunits including NF-YA, NF-YB, and NF-YC; it is a critical transcriptional regulator of lipid and glucose metabolism and adipokine biosynthesis that are associated with type 2 diabetes mellitus (T2DM) occurrence, while the impacts of genetic variants in the NF-Y gene on the risk of T2DM remain to be investigated.
|
31205951 |
2019 |
|
Anaplastic thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TFs including E2F7, FOXM1, CREB3L1, and NFYB were likely to be master regulators of ATC progression, suggesting their potential role as molecular therapeutic targets in ATC treatment.
|
31183379 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
|
29203250 |
2018 |
|
Acute myocardial infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One haplotype, HAP3, was associated with decreased mortality one year after AMI (adjusted HR = 0.42, 95% CI 0.26, 0.68; p = 0.0004).
|
30097758 |
2018 |
|
Hospital acquired pneumonia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study investigated the risk of developing HAP in ED patients and compared the occurrence of HAP 3⁻10 days after the first day of hospitalization in patients hospitalized via ED with those hospitalized via outpatient clinics.
|
29874845 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
|
29203250 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, we found that transcriptional repression mediated by IER5 regulates Cdc25B expression levels via the release of NF-YB and p300 in AML-derived ALDH(hi)/CD34(+) cells, resulting in inhibition of AML progenitor cell proliferation through modulation of cell cycle.
|
22132193 |
2011 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
We did not find protective effects of Hap3 against lung cancer, despite an adequately powered design for this main effect.
|
19282111 |
2009 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
We did not find protective effects of Hap3 against lung cancer, despite an adequately powered design for this main effect.
|
19282111 |
2009 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
We did not find protective effects of Hap3 against lung cancer, despite an adequately powered design for this main effect.
|
19282111 |
2009 |
|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vitro expression analysis using neuroblastoma SK-N-SH cells resulted in a significant decrease in expression of the HAP 3' UTR luc construct compared with the LAP 3' UTR construct.
|
18214604 |
2008 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vitro expression analysis using neuroblastoma SK-N-SH cells resulted in a significant decrease in expression of the HAP 3' UTR luc construct compared with the LAP 3' UTR construct.
|
18214604 |
2008 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vitro expression analysis using neuroblastoma SK-N-SH cells resulted in a significant decrease in expression of the HAP 3' UTR luc construct compared with the LAP 3' UTR construct.
|
18214604 |
2008 |